Algernon Pharmaceuticals Announces Database Lock in Phase 2 Study of IPF and Chronic Cough
13 juin 2022 07h00 HE
|
Algernon Pharmaceuticals
VANCOUVER, British Columbia, June 13, 2022 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGWO) (OTCQB: AGNPF) a clinical stage pharmaceutical...